Expression of Somatostatin Receptors on GEP-NET Cells: Potential Utility for Precision Medicine

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are slow-growing tumors that express high levels of somatostatin receptors (SSTRs), particularly SSTR types 1 and 2 (SSTR1 and SSTR2).1


SSTR is highly expressed in the majority (87-92%) of patients with NETs.2


NETs are frequently only discovered when metastatic or locally advanced, and therefore inoperable.2


SSTR-targeted radioligands may offer a phenotypic precision medicine approach by using the same cell surface biomarker to visualize a tumor via precision imaging and to potentially deliver a therapy to the tumor and surrounding cells.2


SSTR is a transmembrane protein that is highly expressed in NET cells.1,2


References: 1. Reubi JC, Waser B. Shaer JC, Laissue JA. Eur J Nucl Med. 2001;28:836-846; 2. Zaknun JJ, Bodei L, Mueller-Brand J, et al. Eur J Nucl Med Mol Imaging. 2013;40:800-816.